Prof Michelle Haber announced as inaugural Fellow of the Australian Academy of Health & Medical Sciences
March 26, 2015
Children’s Cancer Institute is pleased to announce that our Executive Director, Professor Michelle Haber AM, has been elected as a Fellow of the newly formed Australian Academy of Health & Medical Sciences (AAHMS).
AAHMS is a recently established learned Academy that will provide leadership and independent policy advice in relation to health and medical science in Australia.
The Academy considers nominees for election to the Fellowship who have demonstrated distinguished professional achievement in a field related to health and/or medicine. Prof Haber is one of only 116 inaugural Fellows in the country, who represent a range of disciplines in health and medical research. The group was officially inducted in to the Academy last night in Canberra by Australian Minister for Health, the Hon Sussan Ley MP.
“I’m honoured to have been recognised in this way by such an innovative organisation as AAHMS – and look forward to contributing to the Academy’s objective of developing practices for the best possible health outcomes for all Australians,” says Prof Haber.
The Academy was established formally in June 2014, with the election of 15 initial Fellows and Council members, under the presidency of Professor Ian Frazer and the patronage of Professor Sir Gustav Nossal.
Picture (L-R): Prof Angel Lopez, co-Director, Centre for Cancer Biology; Prof Michelle Haber, Executive Director, Children’s Cancer Institute; Prof Joseph Trapani, Executive Director, Peter MacCallum Cancer Centre
About Children’s Cancer Institute
Originally founded by two fathers of children with cancer in 1976, Children’s Cancer Institute is the only independent medical research institute in Australia wholly dedicated to research into the causes, prevention and cure of childhood cancer. Forty years on, our vision remains unchanged – to save the lives of all children with cancer and to eliminate their suffering. The Institute has grown to now employ more than 220 researchers, operational staff and students, and has established a national and international reputation for scientific excellence.
Our focus is on translational research, and we have an integrated team of laboratory researchers and clinician scientists who work together in partnership to discover new treatments which can be progressed from the lab bench to the beds of children on wards in our hospitals as quickly as possible. These new treatments are specifically targeting childhood cancers, so we can develop safer and more effective drugs and drug combinations that will minimise side-effects and ultimately give children with cancer the best chance of a cure with the highest possible quality of life.
We are currently leading the establishment of the Zero Childhood Cancer national child cancer personalised medicine program for children with the most aggressive cancers, in partnership with the Sydney Children’s Hospitals Network. This program will revolutionise the way treatment decisions are made, with the aim of improving survivorship for those children at highest risk of treatment failure from their disease.